Latest Market News

Omnia Metals Group has successfully issued 54 million shares, raising $1.08 million as part of a broader $1.58 million placement. The company now looks to shareholders for approval to complete the remaining share and option issues.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Nick Scali Limited reported a robust $62 million underlying profit for FY25, completed its UK acquisition equity raise, and announced key leadership changes as it eyes accelerated growth in FY26.

Rincon Resources has completed a significant drilling campaign at its Telfer South Gold Project, testing extensions well beyond its initial resource footprint, while early Laverton drilling results show modest gold grades. Assay results expected soon will be pivotal for the company’s next exploration phase.

Arafura Rare Earths has successfully raised A$475 million through a two-tranche institutional placement, backed by major investors including Hancock Prospecting, to fund the development of its Nolans Project.

Whitebark Energy’s fresh petrophysical analysis reveals significant dry gas zones in its Warro Gas Field, boosting its commercial prospects and prompting a $750,000 capital raise to fast-track development.

Centuria Industrial REIT has secured a landmark 10-year lease with Tesla, delivering a 133% re-leasing spread and deferring redevelopment plans, while pursuing a major data centre expansion in Victoria.

HyTerra Ltd has successfully completed drilling and appraisal operations in Kansas, revealing elevated hydrogen and helium concentrations that reinforce the potential of its Nemaha Project. The company is advancing its US market presence with an OTCQB listing and strategic advisory appointments.

Smart Parking Limited reports a record FY25 with revenues up 42% to $77.2 million, driven by organic growth and strategic acquisitions including Peak Parking in the US. The company targets 3,000 managed sites by 2028, leveraging proprietary AI technology across multiple international markets.

CVC Limited is contemplating a fresh offer of Capital Notes, potentially including a reinvestment option for existing holders, contingent on market and regulatory conditions.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.